Eight years after becoming the CEO of Outset Medical (Nasdaq:OM) and two years after going public, Leslie Trigg says the medtech developer is finally at the starting gate for home dialysis.
It hasn’t been easy. The COVID-19 pandemic made it unsafe to train nurses in person, even as hospitals used the Tablo hemodialysis console in hallways and waiting rooms to clean patients’ blood. The pandemic also disrupted Outset’s supply chain. For example, it increased transportation costs for its single-use cartridges made by a contract manufacturer in Southeast Asia.
Last year, Outset had to put new shipments on hold while working through issues with the FDA.
And when she first go…